Maplight Therapeutics (NASDAQ:MPLT) Director Purchases $77,694.54 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov purchased 4,422 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were purchased at an average price of $17.57 per share, with a total value of $77,694.54. Following the completion of the purchase, the director owned 15,080 shares in the company, valued at approximately $264,955.60. This trade represents a 41.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

George Pavlov also recently made the following trade(s):

• On Friday, February 20th, George Pavlov acquired 9,920 shares of Maplight Therapeutics stock. The shares were acquired at an average cost of $17.86 per share, with a total value of $177,171.20.
• On Wednesday, February 18th, George Pavlov purchased 10,658 shares of Maplight Therapeutics stock. The stock was bought at an average price of $17.48 per share, with a total value of $186,301.84.

Maplight Therapeutics Stock Down 0.2%

Maplight Therapeutics stock opened at $17.88 on Monday. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $21.55. The stock has a market cap of $811.22 million and a price-to-earnings ratio of -0.48. The business has a 50 day moving average price of $17.93.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Hedge Funds Weigh In On Maplight Therapeutics

A number of institutional investors have recently modified their holdings of MPLT. T. Rowe Price Investment Management Inc. purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at $49,168,000. Invesco Ltd. bought a new position in Maplight Therapeutics during the 4th quarter worth about $228,000. Vestal Point Capital LP purchased a new position in Maplight Therapeutics during the 4th quarter valued at about $6,763,000. Tudor Investment Corp ET AL bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $840,000. Finally, Orbimed Advisors LLC purchased a new stake in shares of Maplight Therapeutics in the 4th quarter worth approximately $952,000.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Stifel Nicolaus started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $28.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 price target for the company. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Leerink Partners began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Zacks Research upgraded Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.